Quote | Werewolf Therapeutics Inc. (NASDAQ:HOWL)
Last: | $2.61 |
---|---|
Change Percent: | 0.69% |
Open: | $2.86 |
Close: | $2.61 |
High: | $2.9864 |
Low: | $2.605 |
Volume: | 386,527 |
Last Trade Date Time: | 06/24/2024 03:00:00 am |
News | Werewolf Therapeutics Inc. (NASDAQ:HOWL)
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete respon...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body ...
Message Board Posts | Werewolf Therapeutics Inc. (NASDAQ:HOWL)
Subject | By | Source | When |
---|---|---|---|
Watch list addition, this has the potential to | Mr. Zen | investorshub | 01/16/2023 11:04:36 AM |
$HOWL: Hey thanks....... now 3.20. | makinezmoney | investorshub | 01/11/2023 5:09:32 PM |
Good call here, looking very good | Makk1 | investorshub | 01/11/2023 3:56:09 PM |
$HOWL: Looks like its turning...... now 2.25 | makinezmoney | investorshub | 01/06/2023 2:39:00 PM |
I agree and it looks like share price | bobbo5 | investorshub | 12/16/2022 6:52:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Werewolf Therapeutics Inc. Company Name:
HOWL Stock Symbol:
NASDAQ Market:
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete respon...
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body ...
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - - Preliminary data on WTX-124 administered in combination with pembrolizumab show similar t...